Quad 7 Capital Blog | Talkmarkets | Page 1
Quad 7 Capital is the pioneer of BAD BEAT Investing
Contributor's Links: BAD BEAT Investing

Quad 7 Capital, parent company of Quad 7 Research and Quad 7 Poker, was founded in 2017 by a long time investor, professor and politician. The company has expertise in policy, economics, mathematics, game theory and the sciences. Quad 7 Capital runs a top-rated exclusive research service called ... more


Latest Posts
1 to 16 of 125 Posts
1 2 3 ... 8
TrustCo Bank A Solid Buy Under $8
This is a well-run regional bank, paying a near 3.5% dividend yield. A price target of $7.50 is a great price to buy at.
E Castlight Absolutely Crushed. Profit From This Bad Beat
Management changes following bad news on earnings led to a sell-off. 80-85% of the time Castlight stock bounces 10-15% off the lows following a 40% or more decline in one day.
E Exact Sciences Is Going Higher
With the merger of Exact Sciences and Genomic Health, investors should be looking for EXAS earnings positive results by the end of 2020. In the meantime, revenue growth continues to be astounding.
E GTT Communications: Beaten Down And Primed For A Bounce
GTT Communications is a telecom company that is on our radar after some big declines.We believe that shares have fallen too far too fast on the same news after the latest quarter, in addition to a recent short report. Investors can expect a bounce.
Party City: Excellent Trading Opportunity
This is a value story and we expect a sizable bounce once again following this selloff on no real news. Even with a big helium shortage the possible impacts are not nearly enough to justify the massive selloff since the last earnings report
This Auto Parts Play Should Bounce
We anticipate sales of $9.7-$9.8 billion in 2019 with comparable sales growth of 1.5%-2.5%. With operating margins of over 8%, and not even counting share repurchases, we believe adjusted EPS will approximate $8.25-$8.50, making AAP a buy.
E Varonis: A Cybersecurity Stock Set To Rally
Varonis is transitioning from perpetual licenses to a subscription-based model. This is quite similar to what many others have done, yet the stock has been crushed. We believe a rally in shares continues, as the addressable market is sizable.
Is The Bitcoin Rally For Real?
Bitcoin has again rocketed up past $4,000 per bitcoin, giving fresh hope to long-suffering investors who have been stuck in a bear market for over a year—the second weekend in a row the bitcoin price has rallied. But will it last?
E This Specialty Oil Play Is Unique And Is Poised To Move Higher
We believe HollyFrontier Corporation shares are undervalued, and have been buying in a pyramid style fashion on the way down, while also owning some protective puts which have given profit. This is a specialty play in a niche market. We are bullish.
E What We'd Pay For Hershey
We'd love a 3.5% yield, but this would require a decline into the mid-$80s for HSY stock. Should the market tank, this could happen, and a defensive stock like Hershey would be much more attractive. $82 is the price we would pay for this stock.
E CarMax In 2019
Carmax has been a great vehicle for trading, while investments in the last year or so have mostly moved sideways. In either case however, we think the name is set to move higher and getting shares here at $58.01 is great proposition.
E A Perspective About Tiffany & Co.
We continue to like the name long-term, but shares are a bit ahead of themselves for a new purchase. Given the historic volatility in the name however, we believe that you will get the chance buy shares in the luxury retailer in the future.
E Applied Materials Is A Buy
We believe any time Applied Materials dips under $50 the name is a buy. Shares are facing pressure over ongoing concerns with China, and outlook concerns, despite the outlook being positive. We like what we see from a technical and fundamental view.
E Nuance: A Powerhouse Mean Reversion Buy
Nuance is an artificial intelligence company that is transitioning to focus on its flagship Dragon Drive AI system. This is a mean reversion trade. The fundamentals will improve, but from a technical perspective, this trade looks to set up nicely.
E Buy Jounce For A Bounce
Jounce Therapeutics announced it will present data at the ASCO conference for its candidate JTX-2011, and the Street interpreted the abstract negatively. We see this selloff as an overreaction, and one we can take a gamble on.
E Amedica: Buy For A Bounce
The stock flew on solid scientific news, probably too high. Now it has pulled back almost to where it started after raising cash, we think is a significant overreaction, so we are playing a mean reversion bounce.
1 to 16 of 125 Posts
1 2 3 ... 8